Literature DB >> 6113550

The lack of a pronounced preference of prenalterol for the beta-l-adrenoceptor subtype.

N Rohm, J Wagner, H J Schümann.   

Abstract

The beta-sympathomimetic effect of prenalterol was investigated on the electrically driven left atrium as well as on the tracheal chain of the guinea pig. 1. On the atrium driven at 2 Hz prenalterol caused a positive inotropic effect with a pD2-value of 7.0 +/- 0.08 (N = 4). Compared to isoprenaline (1.0) its intrinsic activity amounted to 0.3. 2. On the tracheal chain prenalterol caused very little relaxation. Its intrinsic activity was virtually negligible when compared with those of fenoterol (1.0) or noradrenaline (1.0); it amounted to 0.07 only. 3. On the atrium the positive inotropic effect of prenalterol vanished after 1 hour of incubation. At this time the concentration-response curve for isoprenaline was shifted dose-dependently to the right. The pD2-value for isoprenaline was significantly diminished (P less than 0.001) by prenalterol, 10(-6)M, from 8.36 to 7.14. 4. Likewise, on the trachea prenalterol caused a pronounced, dose-dependent shift of the concentration-response curves for fenoterol as well as for noradrenaline to the right. 5. The results presented here show that on beta-adrenoceptors of the guinea pig prenalterol is acting like a partial agonist in the left atrium, but as full antagonist in the trachea.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6113550     DOI: 10.1007/bf00504235

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  9 in total

1.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters.

Authors:  J M VAN ROSSUM
Journal:  Arch Int Pharmacodyn Ther       Date:  1963

Review 2.  Pharmacological characterization of receptors: its relation to radioligand-binding studies.

Authors:  R F Furchgott
Journal:  Fed Proc       Date:  1978-02

3.  Human pharmacology studies with a new, orally active stimulant of cardiac adrenergic beta-receptors.

Authors:  M Knaus; B Pfister; U C Dubach; P R Imhof
Journal:  Am Heart J       Date:  1978-05       Impact factor: 4.749

4.  Haemodynamic and tolerance studies in man of a new, orally active, selective beta1-adrenoceptor agonist H 80/62.

Authors:  G Johnsson; L Jordö; P Lundborg; O Rönn; I Welin-Fogelberg; J Wikstrand
Journal:  Eur J Clin Pharmacol       Date:  1978-05-31       Impact factor: 2.953

5.  Differentiation of cardiac chronotropic and inotropic effects of beta-adrenoceptor agonists.

Authors:  E Carlsson; C G Dahlöf; A Hedberg; H Persson; B Tångstrand
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

6.  Is prenalterol (H133/80) really a selective beta 1 adrenoceptor agonist? Tissue selectivity resulting from differences in stimulus-response relationships.

Authors:  T P Kenakin; D Beek
Journal:  J Pharmacol Exp Ther       Date:  1980-05       Impact factor: 4.030

7.  Beta-adrenolytic, antiarrhythmic and local anaesthetic effects of phenylephrine.

Authors:  D Reinhardt; J Wagner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

8.  Haemodynamic effects and pharmacokinetics of a new selective beta1-adrenoceptor agonist, prenalterol, and its interaction with metoprolol in man.

Authors:  O Rönn; C Graffner; G Johnsson; L Jordö; P Lundborg; J Wikstrand
Journal:  Eur J Clin Pharmacol       Date:  1979-02-19       Impact factor: 2.953

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03
  9 in total
  2 in total

1.  Effect of prenalterol in asthmatic patients.

Authors:  C G Löfdahl; N Svedmyr
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

2.  beta 1-and beta 2-adrenoceptor stimulatory effects of prenalterol.

Authors:  H Mattsson; T Andersson; E Carlsson; A Hedberg; B Lundgren; T Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.